Blockade of IL-3 is a promising novel strategy for RA therapy
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory
disorder that attacks the joints producing an inflammatory synovitis. About 1% of the world‘s population is afflicted by rheumatoid arthritis, which is associated with high costs and, if not treated appropriately, with a reduction in life expectancy. Current treatment options include small molecules like methotrexate or biologics like TNFa-blockers, but about 20 % of patients show little or no response to currently available therapies or suffer from severe long term side effects like infections (i.e. tuberculosis, viral brain infections) or cancer (i.e. lymphomas). Clearly, an effective RA drug has blockbuster potential as shown by TNFa-blocker Humira® (Abbott Laboratories) with annual worldwide sales of 4.5 Billion USD in 2008 (data by Medtrack).
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Researchers have found brown fat’s “off-switch
Researchers from the University of Southern Denmark, the Novo Nordisk Center for Adipocyte Signaling (SDU), the University of Bonn and the University Hospital Bonn (UKB) have found a protein that…
Combining robotics and ChatGPT
TUM professor uses ChatGPT for choreographies with flying robots. Prof. Angela Schoellig has proved that large language models can be used safely in robotics. ChatGPT develops choreographies for up to…
How the Immune System Learns from Harmless Particles
Our lungs are bombarded by all manner of different particles every single day. Whilst some are perfectly safe for us, others—known as pathogens—have the potential to make us ill. The…
